Dubai Telegraph - Revolution or mirage? Controversy surrounds new Alzheimer's drugs

EUR -
AED 3.865039
AFN 71.961868
ALL 97.885367
AMD 409.705534
ANG 1.898038
AOA 960.733931
ARS 1055.061215
AUD 1.613881
AWG 1.894109
AZN 1.787029
BAM 1.951539
BBD 2.126437
BDT 125.855234
BGN 1.956342
BHD 0.396578
BIF 3110.579445
BMD 1.052283
BND 1.414399
BOB 7.293078
BRL 6.086683
BSD 1.053191
BTN 88.848028
BWP 14.387453
BYN 3.446543
BYR 20624.740218
BZD 2.122845
CAD 1.469502
CDF 3014.78969
CHF 0.929776
CLF 0.037101
CLP 1023.776253
CNY 7.619996
CNH 7.625593
COP 4626.455438
CRC 534.824751
CUC 1.052283
CUP 27.885491
CVE 110.024795
CZK 25.350861
DJF 187.538784
DKK 7.458788
DOP 63.520417
DZD 140.573397
EGP 52.274979
ERN 15.78424
ETB 131.306162
FJD 2.388363
FKP 0.830585
GBP 0.832524
GEL 2.883571
GGP 0.830585
GHS 16.7185
GIP 0.830585
GMD 74.71233
GNF 9078.051459
GTQ 8.13025
GYD 220.338958
HKD 8.189863
HNL 26.613518
HRK 7.506205
HTG 138.346648
HUF 411.186809
IDR 16734.714279
ILS 3.929639
IMP 0.830585
INR 88.911049
IQD 1379.588093
IRR 44293.214291
ISK 145.520299
JEP 0.830585
JMD 166.933965
JOD 0.746386
JPY 162.676061
KES 136.007134
KGS 91.02957
KHR 4249.68174
KMF 491.94202
KPW 947.053999
KRW 1471.222726
KWD 0.323672
KYD 0.877684
KZT 523.167824
LAK 23125.51255
LBP 94319.785398
LKR 306.411046
LRD 190.622024
LSL 19.101997
LTL 3.107117
LVL 0.636515
LYD 5.138732
MAD 10.521031
MDL 19.167154
MGA 4930.189594
MKD 61.546561
MMK 3417.773046
MNT 3575.656436
MOP 8.443666
MRU 41.866002
MUR 48.839087
MVR 16.268296
MWK 1826.195708
MXN 21.380416
MYR 4.698412
MZN 67.293799
NAD 19.101997
NGN 1768.455747
NIO 38.755022
NOK 11.613586
NPR 142.154623
NZD 1.792324
OMR 0.40513
PAB 1.053101
PEN 3.996674
PGK 4.239684
PHP 62.126243
PKR 292.773138
PLN 4.342422
PYG 8247.914831
QAR 3.840515
RON 4.977085
RSD 117.020141
RUB 106.281009
RWF 1452.315514
SAR 3.95054
SBD 8.79238
SCR 14.332083
SDG 632.944958
SEK 11.610939
SGD 1.413951
SHP 0.830585
SLE 23.75528
SLL 22065.84631
SOS 601.88026
SRD 37.282669
STD 21780.126598
SVC 9.214882
SYP 2643.891613
SZL 19.091139
THB 36.458458
TJS 11.216013
TMT 3.682989
TND 3.324243
TOP 2.464553
TRY 36.27081
TTD 7.130433
TWD 34.270209
TZS 2791.031424
UAH 43.426878
UGX 3886.514989
USD 1.052283
UYU 45.021709
UZS 13526.469111
VES 48.861031
VND 26751.65603
VUV 124.929112
WST 2.937543
XAF 654.521833
XAG 0.033884
XAU 0.000395
XCD 2.843846
XDR 0.801343
XOF 654.521833
XPF 119.331742
YER 262.991742
ZAR 19.064031
ZMK 9471.810193
ZMW 29.146091
ZWL 338.834589
  • RBGPF

    59.6900

    59.69

    +100%

  • RYCEF

    -0.0800

    6.61

    -1.21%

  • SCS

    -0.0200

    13.07

    -0.15%

  • BCC

    -0.7700

    137.41

    -0.56%

  • CMSD

    -0.0836

    24.26

    -0.34%

  • JRI

    -0.0300

    13.23

    -0.23%

  • BCE

    -0.3100

    27

    -1.15%

  • CMSC

    -0.0450

    24.52

    -0.18%

  • RIO

    -0.0400

    62.39

    -0.06%

  • NGG

    -0.3100

    63.27

    -0.49%

  • RELX

    -0.1800

    45.11

    -0.4%

  • GSK

    -0.1100

    33.35

    -0.33%

  • BTI

    0.1500

    37.08

    +0.4%

  • AZN

    -0.6000

    63.2

    -0.95%

  • VOD

    0.0200

    8.94

    +0.22%

  • BP

    -0.0100

    29.08

    -0.03%

Revolution or mirage? Controversy surrounds new Alzheimer's drugs
Revolution or mirage? Controversy surrounds new Alzheimer's drugs / Photo: ALAIN JOCARD - AFP/File

Revolution or mirage? Controversy surrounds new Alzheimer's drugs

Two new drugs, the first capable of slowing down the debilitating progression of Alzheimer's disease, have become embroiled in one of the biggest medical controversies in recent years.

Text size:

For their defenders, the drugs lecanemab and donanemab represent the first real chance to fight the disease after decades of research -- for detractors, they are another disappointment after a long line of costly failures.

"We have turned a corner" thanks to these treatments, British biologist John Hardy, who has been studying Alzheimer's since the 1990s, told AFP.

Rob Howard, a professor of old age psychiatry at University College London, was on the other side.

"I think that the drugs have been used to raise false and unrealistic hopes in people with Alzheimer's disease and their families," he said.

These opposing statements sum up the entrenched positions on the recently introduced drugs for Alzheimer's, the most common form of dementia which millions of people across the world suffer from.

Lecanemab, sold under the name Leqembi, was developed by US pharma firms Biogen and Eisai. Donanemab, developed by pharma giant Eli Lilly, is sold as Kisunla.

The controversy has seen countries take different stances on whether to approve the drugs or not.

The United States gave the green light to lecanemab in 2023, then donanemab earlier this year.

However the European Union rejected lecanemab in July, a bad omen for donanemab's chance of approval.

Last month, the UK steered a middle course, approving the use of lecanemab but not making it available on the state National Health Service.

What no one denies is that the two drugs are the most effective Alzheimer's treatments ever -- but their effectiveness is limited.

Both appear to reduce cognitive decline in patients at the onset of their disease by around 30 percent.

While that may seem high, it represents a relatively small difference over the year-and-a-half period when the studies were carried out.

"The benefits are so tiny as to be practically invisible in an individual patient," Howard said.

- Exorbitant cost -

For critics, there are not enough benefits to outweigh the risks of the drugs, which can sometimes cause brain swelling or bleeding that in rare cases has proved fatal.

And they are very expensive. At the prices being charged by Biogen and Eisai in the United States, lecanemab would cost 133 billion euros ($148 billion) if given to all eligible patients in the EU, according to a 2023 study.

Advocates of the drugs, including many neurologists, believe they can offer patients a few more precious months of autonomy.

They also believe that the effectiveness of the drugs could be multiplied if patients started taking them earlier in the disease's progression. This could soon be more practicable as research on diagnosing Alzheimer's more quickly has recently been making significant strides.

The differing national policies could also mean that poorer patients are left behind.

"We will see rich people going to the US" for the drugs, Hardy said.

The debate can be traced back in part to a seminal 1992 article by Hardy about how the disease actually works.

The article argues that clumps of protein called amyloid plaques -- a constant in the brains of Alzheimer's patients -- are not just one element among others, but the main factor triggering the disease.

Over the decades, many drugs targeting these amyloid plaques were developed, all of which failed -- until lecanemab and donanemab.

- Pressure from families -

The scepticism from some quarters about the new drugs could be because the previous ones were defended and even lauded by some, despite their ineffectiveness.

Christian Guy-Coichard, the head of French organisation Formindep which monitors medical conflicts of interest, accused Alzheimer's groups, researchers and pharmaceutical firms of being too close.

But France Alzheimer deputy director Benoit Durand said that very little of its funding came from Biogen/Eisai or Eli Lilly, instead pointing towards pressure for new treatments from patients' families.

"They don't understand" the EU's decision to turn down a breakthrough new drug, Durand told AFP. He also feared that laboratories could lose interest in Alzheimer's disease due to the setbacks.

Even within the pharmaceutical industry, some admit that past failures have not necessarily helped build trust.

A doctor working for Eli Lilly, who spoke on condition of anonymity, blamed its rival Biogen for overstating the benefits of previous treatment Aduhelm. The drug was controversially approved in the US in 2021 before being withdrawn.

"The Aduhelm studies were a mess," the doctor said.

The aftermath "did a lot of harm and sowed chaos in the discipline", the doctor added, pointing the finger at Biogen.

In response, Biogen told AFP that it was complying with "the principles of scientific research as well as legal and regulatory requirements".

But the Eli Lilly doctor defended the new treatments all the same, urging people to look to the future, not the past.

Like other specialists, he also acknowledged that other mechanisms besides amyloids that could be behind Alzheimer's need to be explored.

Given the disease's complexity, it is unlikely that "single-target treatments will achieve substantially larger effects" than lecanemab and donanemab, a group of experts wrote in the Journal of Prevention of Alzheimer's Disease last month.

But the new drugs are a "critical step" in Alzheimer's treatment, they added.

G.Gopinath--DT